139 related articles for article (PubMed ID: 16572483)
1. Muscarinic allosteric modulators: atypical structure-activity-relationships in bispyridinium-type compounds.
Sürig U; Gaal K; Kostenis E; Tränkle C; Mohr K; Holzgrabe U
Arch Pharm (Weinheim); 2006 Apr; 339(4):207-12. PubMed ID: 16572483
[TBL] [Abstract][Full Text] [Related]
2. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
[TBL] [Abstract][Full Text] [Related]
3. Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.
Grossmüller M; Antony J; Tränkle C; Holzgrabe U; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):267-76. PubMed ID: 16362429
[TBL] [Abstract][Full Text] [Related]
4. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
[TBL] [Abstract][Full Text] [Related]
5. Modes of allosteric interactions with free and [3H]N-methylscopolamine-occupied muscarinic M2 receptors as deduced from buffer-dependent potency shifts.
Schröter A; Tränkle C; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):512-9. PubMed ID: 11138843
[TBL] [Abstract][Full Text] [Related]
6. Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents.
Muth M; Sennwitz M; Mohr K; Holzgrabe U
J Med Chem; 2005 Mar; 48(6):2212-7. PubMed ID: 15771463
[TBL] [Abstract][Full Text] [Related]
7. Contribution of lateral substituents in symmetrical and non-symmetrical heptane-bisammonio compounds to the allosteric stabilization of N-methylscopolamine binding to muscarinic M2 receptors.
Staudt M; Tränkle C; Mohr K; Holzgrabe U
Arch Pharm (Weinheim); 2003 Aug; 336(8):385-9. PubMed ID: 14502759
[TBL] [Abstract][Full Text] [Related]
8. Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding.
Muth M; Bender W; Scharfenstein O; Holzgrabe U; Balatkova E; Tränkle C; Mohr K
J Med Chem; 2003 Mar; 46(6):1031-40. PubMed ID: 12620079
[TBL] [Abstract][Full Text] [Related]
9. Cooperative interactions at M2 muscarinic acetylcholine receptors: structure/activity relationships in stepwise shortened bispyridinium- and bis(ammonio)alkane-type allosteric modulators.
Gilsbach R; Grossmüller M; Alptüzün V; Erciyas E; Tränkle C; Holzgrabe U; Mohr K
Neurochem Res; 2003 Apr; 28(3-4):667-73. PubMed ID: 12675159
[TBL] [Abstract][Full Text] [Related]
10. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
[TBL] [Abstract][Full Text] [Related]
11. Divergent modes of action among cationic allosteric modulators of muscarinic M2 receptors.
Tränkle C; Mohr K
Mol Pharmacol; 1997 Apr; 51(4):674-82. PubMed ID: 9106634
[TBL] [Abstract][Full Text] [Related]
12. Search for lead structures to develop new allosteric modulators of muscarinic receptors.
Tränkle C; Kostenis E; Burgmer U; Mohr K
J Pharmacol Exp Ther; 1996 Nov; 279(2):926-33. PubMed ID: 8930201
[TBL] [Abstract][Full Text] [Related]
13. Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine M2 receptors.
Lanzafame A; Christopoulos A; Mitchelson F
J Pharmacol Exp Ther; 1997 Jul; 282(1):278-85. PubMed ID: 9223565
[TBL] [Abstract][Full Text] [Related]
14. Molecular rigidity and potency of bispyridinium type allosteric modulators at muscarinic M2-receptors.
Tränkle C; Elis K; Wiese M; Mohr K
Life Sci; 1997; 60(22):1995-2003. PubMed ID: 9180353
[TBL] [Abstract][Full Text] [Related]
15. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.
Avlani V; May LT; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931
[TBL] [Abstract][Full Text] [Related]
16. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor.
Redka DS; Pisterzi LF; Wells JW
Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors.
Disingrini T; Muth M; Dallanoce C; Barocelli E; Bertoni S; Kellershohn K; Mohr K; De Amici M; Holzgrabe U
J Med Chem; 2006 Jan; 49(1):366-72. PubMed ID: 16392821
[TBL] [Abstract][Full Text] [Related]
18. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.
Matsui H; Lazareno S; Birdsall NJ
Mol Pharmacol; 1995 Jan; 47(1):88-98. PubMed ID: 7838137
[TBL] [Abstract][Full Text] [Related]
19. Search for the pharmacophore of bispyridinium-type allosteric modulators of muscarinic receptors.
Botero Cid MH; Holzgrabe U; Kostenis E; Mohr K; Tränkle C
J Med Chem; 1994 May; 37(10):1439-45. PubMed ID: 8182702
[TBL] [Abstract][Full Text] [Related]
20. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
